Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE.

Kennedy WP, Maciuca R, Wolslegel K, Tew W, Abbas AR, Chaivorapol C, Morimoto A, McBride JM, Brunetta P, Richardson BC, Davis JC Jr, Behrens TW, Townsend MJ.

Lupus Sci Med. 2015 Mar 28;2(1):e000080. doi: 10.1136/lupus-2014-000080. eCollection 2015.

2.

Plasma levels of galectin-3-binding protein reflect type I interferon activity and are increased in patients with systemic lupus erythematosus.

Nielsen CT, Lood C, Ostergaard O, Iversen LV, Voss A, Bengtsson A, Jacobsen S, Heegaard NH.

Lupus Sci Med. 2014 Nov 19;1(1):e000026. doi: 10.1136/lupus-2014-000026. eCollection 2014.

3.

Association between changes in gene signatures expression and disease activity among patients with systemic lupus erythematosus.

Petri M, Fu W, Ranger A, Allaire N, Cullen P, Magder LS, Zhang Y.

BMC Med Genomics. 2019 Jan 9;12(1):4. doi: 10.1186/s12920-018-0468-1.

4.

Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus.

Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD, Park GS, Dong X, Chen W, Kim MH, Weng HH, Furst DE, Gorn A, McMahon M, Taylor M, Brahn E, Hahn BH, Tsao BP.

Arthritis Rheum. 2006 Sep;54(9):2951-62.

5.
6.

Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus.

Landolt-Marticorena C, Bonventi G, Lubovich A, Ferguson C, Unnithan T, Su J, Gladman DD, Urowitz M, Fortin PR, Wither J.

Ann Rheum Dis. 2009 Sep;68(9):1440-6. doi: 10.1136/ard.2008.093146. Epub 2008 Sep 4.

PMID:
18772188
7.

Association of endogenous anti-interferon-α autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus.

Morimoto AM, Flesher DT, Yang J, Wolslegel K, Wang X, Brady A, Abbas AR, Quarmby V, Wakshull E, Richardson B, Townsend MJ, Behrens TW.

Arthritis Rheum. 2011 Aug;63(8):2407-15. doi: 10.1002/art.30399.

8.

Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production.

Morimoto S, Nakano S, Watanabe T, Tamayama Y, Mitsuo A, Nakiri Y, Suzuki J, Nozawa K, Amano H, Tokano Y, Kobata T, Takasaki Y.

Rheumatology (Oxford). 2007 Jul;46(7):1083-6. Epub 2007 May 11.

PMID:
17500077
9.

BAFF (B cell activating factor) transcript level in peripheral blood of patients with SLE is associated with same-day disease activity as well as global activity over the next year.

Zollars E, Bienkowska J, Czerkowicz J, Allaire N, Ranger AM, Magder L, Petri M.

Lupus Sci Med. 2015 Jun 18;2(1):e000063. doi: 10.1136/lupus-2014-000063. eCollection 2015.

10.

Autoantigen microarrays reveal autoantibodies associated with proliferative nephritis and active disease in pediatric systemic lupus erythematosus.

Haddon DJ, Diep VK, Price JV, Limb C, Utz PJ, Balboni I.

Arthritis Res Ther. 2015 Jun 17;17:162. doi: 10.1186/s13075-015-0682-6.

11.

Interferon regulatory factor 3 as key element of the interferon signature in plasmacytoid dendritic cells from systemic lupus erythematosus patients: novel genetic associations in the Mexican mestizo population.

Santana-de Anda K, Gómez-Martín D, Monsivais-Urenda AE, Salgado-Bustamante M, González-Amaro R, Alcocer-Varela J.

Clin Exp Immunol. 2014 Dec;178(3):428-37. doi: 10.1111/cei.12429.

12.

Type I interferon correlates with serological and clinical manifestations of SLE.

Dall'era MC, Cardarelli PM, Preston BT, Witte A, Davis JC Jr.

Ann Rheum Dis. 2005 Dec;64(12):1692-7. Epub 2005 Apr 20.

13.

Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus.

Salazar-Camarena DC, Ortiz-Lazareno PC, Cruz A, Oregon-Romero E, Machado-Contreras JR, Muñoz-Valle JF, Orozco-López M, Marín-Rosales M, Palafox-Sánchez CA.

Lupus. 2016 May;25(6):582-92. doi: 10.1177/0961203315608254. Epub 2015 Sep 29.

PMID:
26424128
14.

Anti-interferon alpha treatment in SLE.

Kirou KA, Gkrouzman E.

Clin Immunol. 2013 Sep;148(3):303-12. doi: 10.1016/j.clim.2013.02.013. Epub 2013 Mar 1. Review.

PMID:
23566912
15.

Autoantibodies against C-reactive protein: clinical associations in systemic lupus erythematosus and primary antiphospholipid syndrome.

Figueredo MA, Rodriguez A, Ruiz-Yagüe M, Romero M, Fernandez-Cruz A, Gomez-de la Concha E, Patiño R.

J Rheumatol. 2006 Oct;33(10):1980-6.

PMID:
17014014
16.

Activation of the Interferon Pathway is Dependent Upon Autoantibodies in African-American SLE Patients, but Not in European-American SLE Patients.

Ko K, Koldobskaya Y, Rosenzweig E, Niewold TB.

Front Immunol. 2013 Oct 1;4:309. doi: 10.3389/fimmu.2013.00309. eCollection 2013.

17.

Association of elevated transcript levels of interferon-inducible chemokines with disease activity and organ damage in systemic lupus erythematosus patients.

Fu Q, Chen X, Cui H, Guo Y, Chen J, Shen N, Bao C.

Arthritis Res Ther. 2008;10(5):R112. doi: 10.1186/ar2510. Epub 2008 Sep 15.

18.

Measurement of autoantibodies in pediatric-onset systemic lupus erythematosus and their relationship with disease-associated manifestations.

Gilliam BE, Ombrello AK, Burlingame RW, Pepmueller PH, Moore TL.

Semin Arthritis Rheum. 2012 Jun;41(6):840-8. doi: 10.1016/j.semarthrit.2011.09.009. Epub 2011 Dec 15.

PMID:
22177108
19.

Preliminary clinical measurement of the expression of B-cell activating factor in Chinese systemic lupus erythematosus patients.

Lin Z, Dan-Rong Y, Xiao-Qing T, Hao W, Hong-Lian G, Xian-Tao K, Ren-Qian Z, Jiyu L.

J Clin Lab Anal. 2007;21(3):183-7.

PMID:
17506477
20.

Elevated Concentrations of Serum Immunoglobulin Free Light Chains in Systemic Lupus Erythematosus Patients in Relation to Disease Activity, Inflammatory Status, B Cell Activity and Epstein-Barr Virus Antibodies.

Draborg AH, Lydolph MC, Westergaard M, Olesen Larsen S, Nielsen CT, Duus K, Jacobsen S, Houen G.

PLoS One. 2015 Sep 24;10(9):e0138753. doi: 10.1371/journal.pone.0138753. eCollection 2015. Erratum in: PLoS One. 2016;11(1):e0148151.

Supplemental Content

Support Center